This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Glaucoma  • Ophthalmological Procedures, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Alan H. Zalta, MD; Ryan T. Smith, MD

Arch Ophthalmol. 2008;126(11):1603-1605.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Simultaneous bilateral acute angle-closure glaucoma (BAACG) is a rare¹ and potentially blinding disease. From 2001² through 2007,³ there have been about 100 reports^1-4 of topiramate-associated secondary BAACG, establishing topiramate as a leading cause of this condition in patients younger than 40 years. In 83 cases of bilateral and 3 cases of unilateral topiramate-associated acute secondary angle-closure glaucoma, 7 patients sustained permanent vision loss.⁴ Topiramate (Topamax; Ortho-McNeil Neurologics, Titusville, New Jersey)⁵ was approved by the Food and Drug Administration to prevent seizures in 1996 and migraine headaches in 2004, but it is also being used off-label for depression and bipolar disorders, neuropathic pain, and weight reduction.⁴ In 2001, a warning was added to the package insert describing a rare syndrome consisting of ciliochoroidal effusion, forward displacement of the lens-iris diaphragm, marked anterior chamber shallowing, acute myopia, and secondary angle-closure glaucoma.¹ This process is . . . [Full Text of this Article]

Report of Cases


Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?